SCHEMBL8290458

SCHEMBL8290458

O=C(N/N=C/c1ccco1)c1cc(-c2ccco2)n[nH]1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 8/20 0.77
MAPT P10636 7/20 0.70
KMT2A Q03164 4/20 0.70
MEN1 O00255 3/20 0.70
NPSR1 Q6W5P4 1/20 0.70
HPGD P15428 2/20 0.69
GAA P10253 1/20 0.69
L3MBTL1 Q9Y468 2/20 0.60
RAB9A P51151 4/20 0.56
NPC1 O15118 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
CTDSP1 Q9GZU7 2/20 0.54
AHR P35869 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
LMNA P02545 2/20 0.54
MCL1 Q07820 2/20 0.54
CYP1A2 P05177 2/20 0.54
KDM4E B2RXH2 2/20 0.52
FAAH O00519 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8290609 0.84 POLB (0.74) POLBMAPTKMT2AMEN1NPSR1
SCHEMBL8291244 0.84 POLB (0.82) POLBMAPTKMT2AMEN1NPSR1
SCHEMBL8292305 0.83 MAPT (0.78) POLBMAPTKMT2AMEN1NPSR1
SCHEMBL8290511 0.81 MAPT (0.68) POLBMAPTKMT2AMEN1NPSR1
SCHEMBL14583780 0.81 POLB (0.67) POLBMAPTKMT2AMEN1NPSR1
SCHEMBL8290434 0.80 ALDH1A1 (0.72) POLBMAPTKMT2AMEN1NPSR1
SCHEMBL18175041 0.78 TP53 (0.70) POLBMAPTKMT2AMEN1HPGD
SCHEMBL8290433 0.78 POLB (0.63) POLBMAPTKMT2AMEN1NPSR1
SCHEMBL8291968 0.78 KMT2A (1.00) POLBMAPTKMT2AMEN1NPSR1
SCHEMBL8291217 0.77 MAPT (0.65) POLBMAPTKMT2AMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 US disclosed
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 US disclosed
WO-2005037257-A2 NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES IMTM GMBH (DE) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037752-A1 Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases DNPEP, PREP, ANPEP POLB 1250/4885MAPT 1400/4885KMT2A 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.